KRAS and adenocarcinoma: Using the KRasG12V mutant to transform murine lung cells Mainardi and coworkers have reached the conclusion that only SPC+ type II cells are permissive to the transforming activity of this KRAS mutant, first forming hyperplastic lesions, progressing first to adenomas and then to adenocarcinomas [259].